Otros idiomas Abbisko Cayman Limited

Acciones

2256

KYG0028A1085

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:16 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3,42 ^HKD	+3,64 %		+12,13 %	-6,30 %

25/04	El medicamento contra el cáncer de hígado de Abbisko Cayman obtiene la designación de medicamento huérfano de la FDA estadounidense	MT
24/04	Abbisko Cayman Limited anuncia la dimisión de Tian Huimin como secretaria conjunta de la empresa	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation	25/04
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary	24/04
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	10/04
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	09/04
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	09/04
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	14/03
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	13/03
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	13/03
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	23/02
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	06/02
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	02/02
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	09/01
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）	09/01
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	03/01
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	03/01
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	14/12
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	14/12
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck	04/12
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	28/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Abbisko Cayman Limited

Acciones

2256

KYG0028A1085

Otros idiomas

Filtros